There have been a lot of shifts lately behind the reasons people start new biotech companies. Academic and nonprofit sources of biomedical...

When was the last time biotech had a really juicy, successful, high-stakes bidding war? Likely the $10.2 billion Pharmasset acquisition...

Digital health is a bit of a catch-all. It encompasses everything from inexpensive exercise- and diet-recording gadgets to sophisticat...

  Since when did “LP” stand for “Lavish Pharma” – as in, lavishing cash upon the life science venture world? Everyone in our corner of...

The wide-open IPO window has given private companies more liquidity options, so maybe it’s no wonder that pharmas are willing to pay more ...

With what seemed to be stellar results from the ARISTOTLE trial, showing the first superiority over warfarin on bleeding and mortality f...